About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Pharmacogenetics and Genomics
›
Top Articles
Pharmacogenetics and Genomics
Pharmacology
,
Biology
,
Genetics
,
Molecular Biology
1.9
(top 9%)
Impact Factor
2.2
(top 9%)
extended IF
90
(top 4%)
H-Index
1.4K
authors
1.4K
papers
47.5K
citations
3.7K
citing journals
26.2K
citing authors
Most Cited Articles of Pharmacogenetics and Genomics
Title
Year
Citations
Doxorubicin pathways: pharmacodynamics and adverse effects
2011
803
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily
2005
640
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
2006
489
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
2008
444
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
2006
366
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
2005
355
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
2005
307
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
2005
298
Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
2009
287
CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure
2007
287
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
2006
285
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
2011
274
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
2007
264
Metformin pathways: pharmacokinetics and pharmacodynamics
2012
256
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury
2007
251
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28
2007
227
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
2008
216
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis
2005
215
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz
2005
203
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
2009
184
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
2011
181
The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability
2005
179
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
2007
173
Valproic acid pathway: pharmacokinetics and pharmacodynamics
2013
172
Cytochrome P450 2C9-CYP2C9
2010
168
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.